Skip to menu Skip to content Skip to footer
Emeritus Professor Maree Smith
Emeritus Professor

Maree Smith

Email: 

Overview

Background

Update Profile

Emeritus Professor Maree Smith AC FTSE FAHMS is a full-time researcher and Director, CIPDD, School of Biomedical Sciences, Faculty of Medicine, The University of Queensland.

In the 12 years prior to her current appointment, Professor Smith led a high-performing team in building the CIPDD and its commercial interface TetraQ, recognized as a unique, GLP-accredited drug development Centre in Australia. Professor Smith has considerable expertise in biomedical discovery/translation with specialist expertise in the novel pain therapeutics discovery/translation field encompassing a portfolio of 16 rodent pain models that mimic individual human pain conditions. This portfolio of models conducted in a purpose-built facility operated in accordance with the requirements of our Quality Management System, making the CIPDD unique in Australia and rare internationally.

In the 15 years prior to establishing the CIPDD, Professor Maree Smith was a full-time academic in the School of Pharmacy. In brief, she joined the School of Pharmacy as a Lecturer in 1989 and was successively promoted through the academic ranks to Professor in 2004. Prior to that she undertook a PhD and early postdoctoral training in clinical pharmacology with specialist expertise in bioanalytical method development, bioanalysis of human plasma samples, drug metabolism and clinical pharmacokinetics. Her second postdoc was in the field of pain management and pain pharmacology.

In the years, 1990-2005, Maree Smith taught in the Drug Discovery stream of the 2nd, 3rd & 4th years of the undergraduate Pharmacy program and she was instrumental in developing innovative courses for the final year of the undergraduate Pharmacy curriculum. She was also instrumental in the development of a course for the M Biotech program at UQ entitled “Quality Systems in Biotechnology” which continues to this day and is a compulsory course in the Program. Maree has successfully advised/co-advised to completion 33 PhD students, 2 Research Masters students and ~50 Honours students. She also served for 14 years as an external evaluator for the TGA.

Maree's Current Research Interests are as follows:

1. Subtle differences in the pathobiology of individual chronic pain conditions

2. Improving preclinical to clinical translation in novel analgesics development

3. Preclinical drug development of novel pain therapeutics

4. Preclinical drug development

Awards

2021 UQ Fellowship

2019 Companion of the Order of Australia (AC) in the Queen's Birthday Honours List

2018 Honorary Bragg Membership (The Royal Institution of Australia)

2016 Bowl of Hygeia Award (Pharmaceutical Society of Australia)

2016 Clunies Ross Knowledge Commercialisation Award (ATSE)

2015 Honoured to be included in inaugural list of Australia's top Innovators; viz Knowledge Nation 100

2015 Inaugural Inductee into the Life Sciences Queensland (LSQ) Hall of Fame

2015 Johnson and Johnson Innovaton AusBiotech Industry Excellen Award - Outstanding Leader category.

2015 Elected Fellow, Australian Academy of Health and Medical Sciences (AAHMS)

2015 Australian Pain Society Distinguished Member Award - For services to the promotion, treatment and science of pain management and lifelong contribution to the Australian Pain Society

2013 UQ Top 5 Inventor - Award by Thomson Reuters and UQ at inaugural Awards

2013 UQ Top 5 Innovator - Award by UniQuest Pty Ltd and UQ at inaugural Awards

2012 Queensland Life Sciences Industry Excellence Award jointly with Dr Jim Aylward

2011 Elected Fellow, Australian Academy of Technological Sciences (ATSE)

2009 Honorary Fellowship, Faculty of Pain Medicine, ANZCA (Australian and New Zealand College of Anaesthetists).

2008 WiT (Women in Technology): Biotech Outstanding Achievement Award

2002 Meritorious Mention for Sustained Excellence in Research Higher Degree Supervision

2001 Meritorious Mention for Sustained Excellence in Research Higher Degree Supervision

Availability

Emeritus Professor Maree Smith is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours), The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research impacts

Maree is a leading researcher internationally in the pain field. Spinifex Pharmaceuticals was formed in 2005 to commercialize her angiotensin II type 2 (AT2) receptor antagonists technology for neuropathic pain and subsequently chronic inflammatory pain. Spinifex was acquired by Novartis in mid-2015 on the basis of successful early phase clinical trials in patients with post-herpetic neuralgia, a type of peripheral neuropathic pain that is often intractable.

Also, she has highly specialized expertise in the pain field encompassing a portfolio of 15 innovative rodent pain models that closely mimic individual human pain conditions. These models combined with the OECD GLP accreditation of the CIPDD facility means that these capabilities are unique in Australia and rare outside of large pharmaceutical companies internationally.

Works

Search Professor Maree Smith’s works on UQ eSpace

339 works between 1979 and 2025

221 - 240 of 339 works

2003

Other Outputs

Methods of treatment and/or prophylaxis

Smith, M. T. and Brown, L. (2003). Methods of treatment and/or prophylaxis. PCT/AU03/00336.

Methods of treatment and/or prophylaxis

2003

Journal Article

Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: Mechanistic studies in embryonic cultured hippocampal neurones

Hemstapat, K., Monteith, G. R., Smith, D. and Smith, M. T. (2003). Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: Mechanistic studies in embryonic cultured hippocampal neurones. Anesthesia & Analgesia, 97 (2), 494-505. doi: 10.1213/01.ANE.0000059225.40049.99

Morphine-3-glucuronide's neuro-excitatory effects are mediated via indirect activation of N-methyl-D-aspartic acid receptors: Mechanistic studies in embryonic cultured hippocampal neurones

2003

Conference Publication

Quantification of morphine, oxycodone, morphine-3-glucuronide and noroxycodone in rat serum by high performance liquid chromatography (HPLC-electrospray mass spectrometry (EMS)

Edwards, S. R. and Smith, M. T. (2003). Quantification of morphine, oxycodone, morphine-3-glucuronide and noroxycodone in rat serum by high performance liquid chromatography (HPLC-electrospray mass spectrometry (EMS). Annual Scientific Meeting of ASCEPT 2003, Sydney, 30 November - 3 December 2003. Melbourne: ASCEPT.

Quantification of morphine, oxycodone, morphine-3-glucuronide and noroxycodone in rat serum by high performance liquid chromatography (HPLC-electrospray mass spectrometry (EMS)

2003

Conference Publication

A fresh approach to neuropathic pain management: From the animal model to the patient

Moore, B., Azzopardi, J., Cabot, P. J., Gray, P., Roufogalis, B. and Smith, M. T. (2003). A fresh approach to neuropathic pain management: From the animal model to the patient. Combined meeting of the Australian Pain Society 24th ASM and New Zealand Pain Society 10th ASM, Christchurch, NZ, 9-13 March 2003. Sydney: Australian Pain Society.

A fresh approach to neuropathic pain management: From the animal model to the patient

2003

Book Chapter

Neurobiology of Pain: Identification of novel targets for new pain management medications

Smith, M. T. (2003). Neurobiology of Pain: Identification of novel targets for new pain management medications. Molecular Pathomechanisms and New Trends in Drug Research. (pp. 302-318) edited by G. Keri and I. Toth. London & New York: Taylor & Francis.

Neurobiology of Pain: Identification of novel targets for new pain management medications

2003

Journal Article

Managing diabetic neuropathy

Smith, M. T. (2003). Managing diabetic neuropathy. Australian Pharmacist, 22 (10), 782-787.

Managing diabetic neuropathy

2003

Conference Publication

Serum concentrations of metabolically-derived oxymorphone are insignificant in diabetic and non-diabetic adult male Dark Agouti rats following subcutaneous oxycodone bolus administration: Comparison with Sprague-Dawley rats

Huang, L., Le, L., Edwards, S. R. and Smith, M. T. (2003). Serum concentrations of metabolically-derived oxymorphone are insignificant in diabetic and non-diabetic adult male Dark Agouti rats following subcutaneous oxycodone bolus administration: Comparison with Sprague-Dawley rats. Annual Scientific Meeting of ASCEPT, Sydney, 30 November - 3 December 2003. Melbourne: ASCEPT.

Serum concentrations of metabolically-derived oxymorphone are insignificant in diabetic and non-diabetic adult male Dark Agouti rats following subcutaneous oxycodone bolus administration: Comparison with Sprague-Dawley rats

2003

Journal Article

The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes

Wei, M., Ong, L., Smith, M. T., Ross, F. B., Schmid, K., Hoey, A., Burstow, D. J. and Brown, L. C. (2003). The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart, Lung and Circulation, 2003 (12), 44-50. doi: 10.1046/j.1444-2892.2003.00160.x

The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes

2003

Journal Article

The neuroexcitatory morphine metabolite, morphine-3-glucuronide (M3G), is not neurotoxic in primary cultures of either hippocampal or cerebellar granule neurones

Hemstapat, K., Smith, S. A., Monteith, G. R. and Smith, M. T. (2003). The neuroexcitatory morphine metabolite, morphine-3-glucuronide (M3G), is not neurotoxic in primary cultures of either hippocampal or cerebellar granule neurones. Pharmacology & Toxicology, 93 (4), 197-200. doi: 10.1034/j.1600-0773.2003.930408.x

The neuroexcitatory morphine metabolite, morphine-3-glucuronide (M3G), is not neurotoxic in primary cultures of either hippocampal or cerebellar granule neurones

2003

Conference Publication

Longitudinal investigation of the antinociceptive potency of oxycodone and morphine in the Zucker rat

Tsui, D. Y., Hawes, S., Patterson, M. and Smith, M. T. (2003). Longitudinal investigation of the antinociceptive potency of oxycodone and morphine in the Zucker rat. Annual Scientific Meeting of Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists 2003, Sydney, 30 November - 3 December 2003. Melbourne: ASCEPT.

Longitudinal investigation of the antinociceptive potency of oxycodone and morphine in the Zucker rat

2002

Journal Article

The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices.

Smith, M. T., Cabot, P. J., Ross, F. B., Robertson, A. D. and Lewis, R. J. (2002). The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices.. Pain, 96 (1-2), 119-127. doi: 10.1016/S0304-3959(01)00436-5

The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices.

2002

Conference Publication

Electrolyte removal from artificial CSF by HPLC to restore ESI-MS/MS signal intensity in quantification of morphine and its glucuronide metabolites

Wells, J. A., Punjanon, T. and Smith, M. T. (2002). Electrolyte removal from artificial CSF by HPLC to restore ESI-MS/MS signal intensity in quantification of morphine and its glucuronide metabolites. 10th World Congress on Pain, San Diego, 17-22 Aug. 2002. Seattle: IASP Press.

Electrolyte removal from artificial CSF by HPLC to restore ESI-MS/MS signal intensity in quantification of morphine and its glucuronide metabolites

2002

Conference Publication

Anti-allodynic efficacy of the x-conipeptide, MR1A, in rats with neuropathic pain

Nielsen, C., Ross, F. B., Lewis, R. J., Drinkwater, R. D. and Smith, M. T. (2002). Anti-allodynic efficacy of the x-conipeptide, MR1A, in rats with neuropathic pain. AHMR Congress 2002, Melbourne, 24-29 Nov. 2002. Melbourne: NHMRC.

Anti-allodynic efficacy of the x-conipeptide, MR1A, in rats with neuropathic pain

2002

Conference Publication

Prolonged oestradiol supplementation does not significantly alter levels of antinociception evoked by ICV morphine in adult male rats

Mather, L. E., Punjanon, T. and Smith, M. T. (2002). Prolonged oestradiol supplementation does not significantly alter levels of antinociception evoked by ICV morphine in adult male rats. 10th World Congress on Pain, San Diego, 17-22 Aug. 2002. Seattle: IASP Press.

Prolonged oestradiol supplementation does not significantly alter levels of antinociception evoked by ICV morphine in adult male rats

2002

Conference Publication

P/Q and L-type calcium channel blockers abolish morphine-3-glucuronide (M3G)-induced indirect activation of the NMDA receptor

Hemstapat, K., Monteith, G. R. and Smith, M. T. (2002). P/Q and L-type calcium channel blockers abolish morphine-3-glucuronide (M3G)-induced indirect activation of the NMDA receptor. AHMR Congress 2002, Melbourne, 24-29 Nov. 2002. Melbourne: NHMRC.

P/Q and L-type calcium channel blockers abolish morphine-3-glucuronide (M3G)-induced indirect activation of the NMDA receptor

2002

Conference Publication

Serum 17 -oestradiol concentrations are directly correlated with the time to reach peak antinociception in oestradiol-pretreated rats administered prolonged intravenous morphine infusions

Le, L., Chmura, P., Mather, L. E. and Smith, M. T. (2002). Serum 17 -oestradiol concentrations are directly correlated with the time to reach peak antinociception in oestradiol-pretreated rats administered prolonged intravenous morphine infusions. 10th World Congress on Pain, San Diego, 17-22 Aug. 2002. Seattle: IASP Press.

Serum 17 -oestradiol concentrations are directly correlated with the time to reach peak antinociception in oestradiol-pretreated rats administered prolonged intravenous morphine infusions

2002

Conference Publication

In vivo investigation of the effects of intracerebroventricular (ICV) morphine-3-glucuronide (M3G) on von frey paw withdrawal thresholds in rats

Le, L., Hemstapat, K. and Smith, M. T. (2002). In vivo investigation of the effects of intracerebroventricular (ICV) morphine-3-glucuronide (M3G) on von frey paw withdrawal thresholds in rats. AHMR Congress 2002, Melbourne, 24-29 Nov. 2002. Melbourne: NHMRC.

In vivo investigation of the effects of intracerebroventricular (ICV) morphine-3-glucuronide (M3G) on von frey paw withdrawal thresholds in rats

2002

Conference Publication

Oxycodone, but not morphine, is efficacious for the relief of tactile allodynia in diabetic rats at three and six months after the induction of diabetes with streptozotocin

Lotfipour, S., Ross, F. B., Saini, K. and Smith, M. T. (2002). Oxycodone, but not morphine, is efficacious for the relief of tactile allodynia in diabetic rats at three and six months after the induction of diabetes with streptozotocin. 10th World Congress on Pain, San Diego, 17-22 Aug. 2002. Seattle: IASP Press.

Oxycodone, but not morphine, is efficacious for the relief of tactile allodynia in diabetic rats at three and six months after the induction of diabetes with streptozotocin

2002

Conference Publication

Supraspinally administered oxycodone has intrinsic anti-allodynic effects for the alleviation of tactile allodynia in adult male rats with streptozotocin-induced diabetes

Smith, M. T., Patterson, M. and Ross, F. B. (2002). Supraspinally administered oxycodone has intrinsic anti-allodynic effects for the alleviation of tactile allodynia in adult male rats with streptozotocin-induced diabetes. 10th World Congress on Pain, San Diego, 17-22 August 2002. Seattle: IASP Press.

Supraspinally administered oxycodone has intrinsic anti-allodynic effects for the alleviation of tactile allodynia in adult male rats with streptozotocin-induced diabetes

2002

Conference Publication

Anti-allodynic efficacy of the conopeptide, MR1A, in rats with neuropathic pain

Nielsen, C., Ross, F. B., Lewis, R. J., Drinkwater, R. D. and Smith, M. T. (2002). Anti-allodynic efficacy of the conopeptide, MR1A, in rats with neuropathic pain. 10th World Congress on Pain, San Diego, 17-22 Aug. 2002. Seattle: IASP Press.

Anti-allodynic efficacy of the conopeptide, MR1A, in rats with neuropathic pain

Funding

Current funding

  • 2024 - 2025
    Novel ionophore combination therapeutic treatment (CARB-X grant administered by University of Melbourne)
    University of Melbourne
    Open grant
  • 2023 - 2028
    Centre for Integrated Preclinical Drug Development (CIPDD) NCRIS 2022 (administered by Therapeutic Innovation Australia (TIA))
    Therapeutic Innovation Australia Limited
    Open grant
  • 2023 - 2026
    Target validation of acid-sensing ion channel inhibitors to stop disease progression and manage pain in MS
    National Multiple Sclerosis Society-US
    Open grant
  • 2023 - 2025
    Breaking drug resistance in community acquired bacterial pneumonia (CABP) (NHMRC Development grant administered by University of Melbourne)
    University of Melbourne
    Open grant
  • 2022 - 2026
    Mining the host-pathogen interface to deliver a drug pipeline for treating intractable and emerging infections
    NHMRC Synergy Grants
    Open grant
  • 2022 - 2025
    Novel long-acting and orally delivered conotoxin-based peptides with both analgesic efficacy and disease modifying potential
    NHMRC Development Grant
    Open grant

Past funding

  • 2022 - 2024
    Dose range finding and main efficacy study for one peptide-drug-conjugate using the MDA-MB-231 cell line-based xenograft mouse model of triple negative breast cancer
    University of Sydney
    Open grant
  • 2022 - 2024
    Assess the clinical disease-modifying effects of one peptide test item given twice-weekly for 3 weeks relative to sham control and vehicle in the relapsing-remitting experimental autoimmune encephalom
    Argenica Therapeutics Limited
    Open grant
  • 2022 - 2024
    Developing novel acid-sensing ion channel inhibitors as neuroprotective leads and diagnostic agents for multiple sclerosis
    Multiple Sclerosis Research Australia - Targeted Grant - Neurodegeneration
    Open grant
  • 2020 - 2022
    Neuroprotective role of novel acid-sensing ion channel inhibitor in Multiple sclerosis (MS) disease
    Multiple Sclerosis Research Australia
    Open grant
  • 2019
    Advanced Brightfield and Fluorescent High Speed and Throughput Slide Scanner for biological, medical, materials science, and agricultural applications
    UQ Major Equipment and Infrastructure
    Open grant
  • 2019 - 2021
    Development of a first-in-class neuroprotective drug for protecting the brain after stroke
    NHMRC Development Grant
    Open grant
  • 2019
    Vevo 3100 Imaging System for ultrahigh resolution and frame rate echocardiographic assessment of small animals.
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018
    High-throughput ion channel pharmacology
    UQ Major Equipment and Infrastructure
    Open grant
  • 2018 - 2020
    Novel non-opioid analgesics
    NHMRC Development Grant
    Open grant
  • 2017 - 2018
    The impact of extracorporeal membrane oxygenation (ECMO) on the activities of drug enzymes that affect the pharmacokinetics and therapeutic outcomes of clinically important drugs
    Prince Charles Hospital Foundation
    Open grant
  • 2016
    Novel Pain therapeutics discovery: Probing molecular mechanisms
    NHMRC Equipment Grant
    Open grant
  • 2016 - 2019
    Novel prolonged-release polymeric microparticles for relief of intractable cancer-related pain
    NHMRC Project Grant
    Open grant
  • 2015 - 2016
    INK-004 Preliminary assessment of the analgesic efficacy of one test item following intrathecal bolus administration in a rat model of peripheral neuropathic pain
    UniQuest Pty Ltd
    Open grant
  • 2015 - 2022
    ACRF Facility for Molecular Imaging Agents in Cancer (AFMIAC)
    Australian Cancer Research Foundation
    Open grant
  • 2015
    Novel analgesics for improved relief of cancer induced bone pain
    UQ Collaboration and Industry Engagement Fund - Seed Research Grant
    Open grant
  • 2014 - 2015
    PHG-003 - Preparation of manuscript encompassing the data generated in studies PHG-001 and PHG-002 for publication in an international peer-reviewed journal
    UniQuest Pty Ltd
    Open grant
  • 2014 - 2023
    Translating Health Discovery (THD) - NCRIS 2013/2015/2016-17/2017-18/2018-19/2019-23 (administered by Therapeutic Innovation Australia (TIA))
    Therapeutic Innovation Australia Limited
    Open grant
  • 2014 - 2017
    Developing subtype-selective blockers of acid-sensing ion channels for treating peripheral pain
    NHMRC Project Grant
    Open grant
  • 2013 - 2016
    Investigations into the pain relief properties of Komipharm's test compound
    UniQuest Pty Ltd
    Open grant
  • 2013 - 2014
    Novel analgesics for improved treatment of chronic cancer pain
    Queensland Emory Development Alliance
    Open grant
  • 2013 - 2015
    Oral EMA401 mode of action study in a rat model of post-herpetic neralgia (PHN)
    Spinifex Pharmaceuticals Pty Ltd
    Open grant
  • 2013 - 2018
    Efficacy Profiling Innovation in Novel Pain Therapeutics Discovery
    ARC Linkage Projects
    Open grant
  • 2011 - 2014
    Therapeutic Innovation Australia - Queensland node (Source of funds: EIF)
    Therapeutic Innovation Australia Limited
    Open grant
  • 2011 - 2015
    Translating health discoveries into products
    Queensland Government Smart Futures Co-Investment Fund
    Open grant
  • 2010 - 2012
    Development of high throughput in-vitro test methods for screening sensitization potential of industrial chemicals
    UQ Collaboration and Industry Engagement Fund
    Open grant
  • 2010 - 2013
    Novel polymeric microparticles for slow-release intrathecal delivery of analgesics
    ARC Linkage Projects
    Open grant
  • 2010 - 2013
    Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases
    ARC Linkage Projects
    Open grant
  • 2010
    Cost effective acquisition of an LC-MS/MS system to support CIPDD organics analysis and preclinical and clinical operations
    UQ Major Equipment and Infrastructure
    Open grant
  • 2010
    High content imaging analysis for bioactive and novel therapeutic target evaluation
    UQ Major Equipment and Infrastructure
    Open grant
  • 2009 - 2010
    Systematic evaluation of whether in vitro methods can predict in vivo opioid analgesic efficacy, safety and teolerability
    Alchemia Pty Ltd
    Open grant
  • 2009 - 2013
    Alzheimer's disease: Novel MRI Biomarkers for Clinical Diagnosis and Translational Studies
    Queensland Government Smart State National and International Research Alliances Program
    Open grant
  • 2009
    Robotics Instrumentation for High Throughput Sample preparation for Increased Productivity of the CIPDD/TetraQ's HPLC-MS/MS Systems for Quantitative Analysis of Organics in a Quality Systems NATA-Acc
    UQ Faculty Co-Funding
    Open grant
  • 2008
    Investigation of the relationship between cytokine levels and opioid analgesics in patients with chronic non-cancer pain receiving long term intrathecal opioid therapy for pain management
    Gallipoli Research Foundation
    Open grant
  • 2008
    Novel therapeutic for treating painful diabetic neuropathy
    Diabetes Australia Research Trust
    Open grant
  • 2006 - 2007
    Investigation of whether a small dose of Oxycodone enhances the efficacy and/or tolerability of orally administered pregabalin in patients with either post-herpetic neuralgia (PHN) or painful diabetic
    Gallipoli Research Foundation
    Open grant
  • 2006 - 2009
    Systematic evaluation of whether in vitro methods can predict in vivo opioid analgesic efficacy, safety and tolerability
    ARC Linkage Projects
    Open grant
  • 2006
    Advanced Cell Labelling and Imaging Facility
    ARC Linkage Infrastructure, Equipment and Facilities
    Open grant
  • 2005
    NHMRC_Equipment Grant = DSI Telemetry System
    NHMRC Equipment Grant
    Open grant
  • 2004 - 2005
    The analgesic evaluation of novel natural products from the Australian plant Barringtonia acutangula
    Griffith University
    Open grant
  • 2004 - 2005
    NHMRC_Equipment Grant_HLTH_Pharmacy
    NHMRC Equipment Grant
    Open grant
  • 2004
    Synthesis And Pharmacological Evaluation Of Strong Opioid Analgesics With Improved Side-Effect Profiles
    University of Queensland Research Development Grants Scheme
    Open grant
  • 2003
    Evaluation Of Intravenous Oxycodone As An Analgesic In Dogs: Pharmacodynamic/Pharmacokinetic And Dose Ranging Studies
    University of Queensland Research Development Grants Scheme
    Open grant
  • 2003
    Malvern Zetasizer 3000HS
    NHMRC Equipment Grant
    Open grant
  • 2002 - 2003
    Pharmacological investigation of the toxicological effects of high doses of systemic morphine
    Queensland Cancer Fund
    Open grant
  • 2001 - 2002
    Prevention of chronic complications in the STZ-diabetic rat
    Mayne Bequest Fund
    Open grant
  • 2001 - 2004
    Lipid and liposaccharide based drug delivery systems
    Wellcome Trust
    Open grant
  • 2001
    A biohazard laminar flow hood for neuronal cell cultures:partial cost recovery from emergency purchase
    Brain Research Fund
    Open grant
  • 2001
    Neuro-excitatory side-effects of high-dose systemic morphine in cancer patients: mechanistic studies.
    Cancer Bequest Fund
    Open grant
  • 1999 - 2002
    A novel liposaccharide based system for drug/peptide delivery
    Wellcome Trust
    Open grant
  • 1999
    The use of fluorescence microscopy to investigate the role of the calcium pump in disease and the mechanism of excitatory side effects by high dose morphine
    Ramaciotti Foundation
    Open grant
  • 1998 - 1999
    Further investigation of morphine 3-glucuronide's role in the dose-limiting excitatory side-effects of morphine administered chronically to cancer patients
    Queensland Cancer Fund
    Open grant
  • 1998 - 2000
    M3G: Further Studies of its CNS Pharmacology
    NHMRC Project Grant
    Open grant
  • 1995 - 1997
    Investigation of the CNS mechanisms involved in the excitatory side-effects of Morphine in cancer pain management
    Queensland Cancer Fund
    Open grant

Supervision

Availability

Emeritus Professor Maree Smith is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Pathobiology of Neuropathic (nerve damage) Pain

  • Novel neuropathic pain therapeutics discovery

  • Painful Diabetic Neuropathy: Towards Improved Drug Treatments

Supervision history

Current supervision

Completed supervision

Media

Enquiries

Contact Emeritus Professor Maree Smith directly for media enquiries about:

  • Bioanalysis - drugs
  • Clinical trials - drug development
  • Drug analysis
  • Drug development
  • Efficacy models - pharmacology
  • Opioid pharmacology
  • Pain management - pharmacy
  • Pharmacokinetics
  • Pharmacology
  • Pharmacy
  • Preclinical drug development
  • Preclinical efficacy models

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au